Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

BACKGROUND: Pre-clinical evidence supports the clinical investigation of inhibitors to the insulin-like growth factor receptor (IGFR) and the epidermal growth factor receptor (EGFR) alone and in combination in patients with NSCLC. PATIENTS AND METHODS: Patients with chemotherapy-naïve, advanced NSCL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Hanna, Nasser H., Dahlberg, Suzanne E., Kolesar, Jill, Aggarwal, Charu, Hirsch, Fred R., Ramalingam, Suresh S., Schiller, Joan H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4560671/
https://ncbi.nlm.nih.gov/pubmed/25740387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29308
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados